A bone peptide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Osteocalcin (1-49) (human) (trifluoroacetate salt)

Item No. 24723

Technical Information
Formal Name
L-tyrosyl-L-leucyl-L-tyrosyl-L-glutaminyl-L-tryptophyl-L-leucylglycyl-L-alanyl-L-prolyl-L-valyl-L-prolyl-L-tyrosyl-L-prolyl-L-α-aspartyl-L-prolyl-L-leucyl-4-carboxy-L-α-glutamyl-L-prolyl-L-arginyl-L-arginyl-4-carboxy-L-α-glutamyl-L-valyl-L-cysteinyl-4-carboxy-L-α-glutamyl-L-leucyl-L-asparaginyl-L-prolyl-L-α-aspartyl-L-cysteinyl-L-α-aspartyl-L-α-glutamyl-L-leucyl-L-alanyl-L-α-aspartyl-L-histidyl-L-isoleucylglycyl-L-phenylalanyl-L-glutaminyl-L-α-glutamyl-L-alanyl-L-tyrosyl-L-arginyl-L-arginyl-L-phenylalanyl-L-tyrosylglycyl-L-prolyl-L-valine cyclic (23→29)-disulfide, trifluoroacetate salt
CAS Number
136461-80-8
Molecular Formula
C269H381N67O82S2 • XCF3COOH
Formula Weight
Purity
≥95%
A lyophilized powder
Formic Acid: 1 mg/ml
SMILES
OC(C(C(O)=O)C[C@@H](C(N1CCC[C@H]1C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C(O)=O)C(O)=O)C(N[C@@H](C(C)C)C(N[C@H](C(N[C@@H](CC(C(O)=O)C(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N2CCC[C@H]2C(N[C@H](C3=O)CC(O)=O)=O)=O)=O)=O)=O)CSSC[C@H](N3)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@]([C@H](CC)C)([H])C(NCC(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(NCC(N4CCC[C@H]4C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)CC5=CC=C(O)C=C5)=O)CC6=CC=CC=C6)=O)=O)=O)CC7=CC=C(O)C=C7)=O)C)=O)=O)=O)CC8=CC=CC=C8)=O)=O)=O)CC9=CN=CN9)=O)CC(O)=O)=O)C)=O)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CC(C)C)NC([C@@H]%10CCCN%10C([C@@H](NC([C@@H]%11CCCN%11C([C@@H](NC([C@@H]%12CCCN%12C([C@H](C(C)C)NC([C@@H]%13CCCN%13C([C@@H](NC(CNC([C@H](CC(C)C)NC([C@@H](NC([C@H](CCC(N)=O)NC([C@@H](NC([C@H](CC(C)C)NC([C@@H](N[H])CC%14=CC=C(O)C=C%14)=O)=O)CC%15=CC=C(O)C=C%15)=O)=O)CC%16=CNC%17=C%16C=CC=C%17)=O)=O)=O)C)=O)=O)=O)=O)CC%18=CC=C(O)C=C%18)=O)=O)CC(O)=O)=O)=O)=O)=O.FC(F)(C(O)=O)F
InChi Code
InChI=1S/C269H381N67O82S2.C2HF3O2/c1-22-136(18)213(251(397)289-123-202(346)295-174(104-140-42-25-23-26-43-140)231(377)300-164(79-83-198(271)342)224(370)299-166(81-85-204(348)349)219(365)293-137(19)214(360)304-175(107-144-63-73-151(339)74-64-144)232(378)298-160(48-31-87-283-266(274)275)220(366)296-161(49-32-88-284-267(276)277)222(368)311-176(105-141-44-27-24-28-45-141)234(380)310-173(106-143-61-71-150(338)72-62-143)218(364)290-124-203(347)330-91-35-52-191(330)249(395)328-212(135(16)17)265(417)418)329-240(386)179(111-148-121-282-127-291-148)314-238(384)182(116-206(352)353)305-215(361)138(20)294-227(373)169(99-129(4)5)308-226(372)167(82-86-205(350)351)302-237(383)183(117-207(354)355)317-242(388)189-125-419-420-126-190(243(389)316-180(112-155(259(405)406)260(407)408)236(382)309-171(101-131(8)9)229(375)321-187(115-200(273)344)256(402)334-95-38-55-194(334)246(392)319-184(118-208(356)357)239(385)324-189)325-252(398)210(133(12)13)326-241(387)181(113-156(261(409)410)262(411)412)315-223(369)162(50-33-89-285-268(278)279)297-221(367)163(51-34-90-286-269(280)281)303-244(390)192-53-37-94-333(192)255(401)186(114-157(263(413)414)264(415)416)320-230(376)172(102-132(10)11)318-245(391)193-54-39-96-335(193)257(403)188(119-209(358)359)323-247(393)195-56-40-93-332(195)254(400)185(109-146-67-77-153(341)78-68-146)322-248(394)196-57-41-97-336(196)258(404)211(134(14)15)327-250(396)197-58-36-92-331(197)253(399)139(21)292-201(345)122-288-217(363)168(98-128(2)3)307-235(381)178(110-147-120-287-159-47-30-29-46-154(147)159)313-225(371)165(80-84-199(272)343)301-233(379)177(108-145-65-75-152(340)76-66-145)312-228(374)170(100-130(6)7)306-216(362)158(270)103-142-59-69-149(337)70-60-142;3-2(4,5)1(6)7/h23-30,42-47,59-78,120-121,127-139,155-158,160-197,210-213,287,337-341H,22,31-41,48-58,79-119,122-126,270H2,1-21H3,(H2,271,342)(H2,272,343)(H2,273,344)(H,282,291)(H,288,363)(H,289,397)(H,290,364)(H,292,345)(H,293,365)(H,294,373)(H,295,346)(H,296,366)(H,297,367)(H,298,378)(H,299,370)(H,300,377)(H,301,379)(H
InChi Key
PCVRZKPLCGSOAT-AJASTJSBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Osteocalcin (1-49) is a non-collagenous peptide that is secreted by osteoblasts and odontoblasts and comprises 1-2% of the total protein in bone.1 Secretion of osteocalcin (1-49) is stimulated by 1,25-dihydroxy vitamin D and plasma levels increase in diseases that induce dysregulated bone turnover such as osteoporosis, Paget's disease, and primary hyperparathyroidism.1,2 Osteocalcin (1-49) is positively correlated with insulin sensitivity and negatively correlated with high blood glucose levels in women.3 In vitro, osteocalcin induces chemotaxis of MDA-MB-231 breast cancer cells, human peripheral blood monocytes, and rat osteosarcoma cells with osteoblast-like characteristics.2 It is also expressed by vascular smooth muscle cells (VSMCs) displaying an osteoblast-like phenotype and has been positively associated with calcification of aortic tissue and heart valves in humans.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Colford, J.W., Lueddecke, B.A., Salvati, M., et alImmunoradiometric assay for intact human osteocalcin(1-49) without cross-reactivity to breakdown products. Clin. Chem. 45(4), 526-531 (1999).

    2. Mundy, G.R., and Poser, J.W. Chemotactic activity of the ɤ-carboxyglutamic acid containing protein in bone. Calcif. Tissue Int. 35(2), 164-168 (1983).

    3. Levinger, I., Seeman, E., Jerums, G., et alGlucose-loading reduces bone remodeling in women and osteoblast function in vitro. Physiol. Rep. 4(3), e12700 (2016).

    4. Millar, S.A., Patel, H., Anderson, S.I., et alOsteocalcin, vascular calcification, and atherosclerosis: A systematic review and meta-analysis. Front. Endocrinol. (Lausanne) 8(183), (2017).